Background:
The potential use of nanocarriers is being explored rapidly for the targeted
delivery of anticancer agents. Curcumin is a natural polyphenolic compound obtained from
rhizomes of turmeric, belongs to family Zingiberaceae. It possesses chemopreventive and chemotherapeutic
activity with low toxicity in almost all types of cancer. The low solubility and bioavailability
of curcumin make it unable to use for the clinical purpose. The necessity of an effective
strategy to overcome the limitations of curcumin is responsible for the development of its nanocarriers.
Objective:
This study is aimed to review the role of curcumin nanocarriers for the treatment of
cancer with special emphasis on cellular uptake and in vitro cytotoxicity studies. In addition to
this, the effect of various ligand conjugated curcumin nanoparticles on different types of cancer
was also studied.
Methods:
A systematic review was conducted by extensively surfing the PubMed, science direct
and other portals to get the latest update on recent development in nanocarriers of curcumin.
Results:
The current data from recent studies showed that nanocarriers of curcumin resulted in the
targeted delivery, higher efficacy, enhanced bioavailability and lower toxicity. The curcumin
nanoparticles showed significant inhibitory effects on cancer cells as compared to free curcumin.
Conclusion:
It can be concluded that bioavailability of curcumin and its cytotoxic effect to cancer
cells can be enhanced by the development of curcumin based nanocarriers and it was found to be a
potential drug delivery technique for the treatment of cancer.
A Novel fusogenic lipid vesicle (FLV) based targeted delivery system displays compstatin on cell membranes and effectively reduces complement deposition in vitro
